Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Changzhou Pharmaceutical Factory, received a drug registration certificate from Chinese drug regulator National Medical Products Administration for its eltrombopag ethanolamine tablets, the company said in its filing on the Shanghai Stock Exchange.
The drug is used as a treatment for patients with chronic immune (idiopathic) thrombocytopenia who have not responded well to treatments such as glucocorticoids and immunoglobulins in the past.
The pharmaceutical company invested 21.6 million yuan into the research and development of the drug, according to the Wednesday filing.
The company's shares rose more than 1% on the Shanghai bourse.
Price (HKD): $19.53, Change: $+0.25, Percent Change: +1.30%
Comments